MIRA Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
MIRA Pharmaceuticals's earnings have been declining at an average annual rate of -52.9%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually.
Key information
-52.9%
Earnings growth rate
-103.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -576.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How MIRA Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -13 | 7 | 3 |
| 31 Mar 24 | 0 | -12 | 7 | 2 |
| 31 Dec 23 | 0 | -12 | 7 | 2 |
| 30 Sep 23 | 0 | -8 | 5 | 2 |
| 30 Jun 23 | 0 | -6 | 4 | 2 |
| 31 Mar 23 | 0 | -7 | 5 | 2 |
| 31 Dec 22 | 0 | -7 | 5 | 2 |
| 31 Mar 22 | 0 | -4 | 2 | 1 |
| 31 Dec 21 | 0 | -2 | 1 | 1 |
Quality Earnings: K6S is currently unprofitable.
Growing Profit Margin: K6S is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: K6S is unprofitable, and losses have increased over the past 5 years at a rate of 52.9% per year.
Accelerating Growth: Unable to compare K6S's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: K6S is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: K6S has a negative Return on Equity (-576.14%), as it is currently unprofitable.